Oxitec
Abingdon
About Oxitec
Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well as agricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $65.4M
- Funding stage: M&A
- Last round: Grant (Apr 2022)
- Website: oxitec.com
- Phone: +44 1235 832393
Industries & Categories
Agriculture, Biotechnology, Chemical, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/oxitec-49944 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.